Literature DB >> 34790398

Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma.

Youli Du1, Xiaoou Ma1, Dongxu Wang2, Yuguang Wang2, Tianyu Zhang2, Lianjie Bai3, Yunlong Liu4, Shaosen Chen4.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common type of liver cancer with a high mortality rate. However, spliceosomal genes are still lacking in the diagnosis and prognosis of HCC.
METHODS: Identification of differentially expressed genes (DEGs) was performed using the limma package in R software. Modules highly related to HCC were obtained by weighted gene co-expression network analysis (WGCNA), and the module genes were analyzed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The biomarker for diagnosing HCC was determined by receiver operating characteristic (ROC) curve analysis, and the effect of the biomarker in the diagnosis of HCC was evaluated by performing five-fold cross-validation with logistic regression. HCC specimens from preoperatively treated patients were tested for biomarker by real-time quantitative polymerase chain reaction (RT-qPCR). Kaplan-Meier analysis was used to assess the relationship between biomarker and patient survival. The role of biomarker was evaluated using ESTIMATE analysis in the tumor microenvironment.
RESULTS: In this study, 389 DEGs were screened out from three Gene Expression Omnibus (GEO) datasets. We also found that the turquoise module of 123 genes from The Cancer Genome Atlas (TCGA) data was the key module with the highest correlation with HCC traits. Then, 123 genes were analyzed using the KEGG enrichment pathway, and eight genes were found to be most significantly related to the spliceosome pathway. We selected 8 genes and 389 DEGs shared genes, and finally got the only gene, heterogeneous nuclear ribonucleoprotein (hnRNPU). The high expression of hnRNPU was associated with poor prognosis of HCC, and hnRNPU was a biomarker for diagnosing HCC. In the tissues of patients with excellent HCC treatment hnRNPU messenger RNA (mRNA) was lower than in the tissues of patients with poor HCC treatment. High expression of hnRNPU was significantly increased in HCC patients with low stromal (P<0.05), low immune (P<0.05), and low estimation scores (P<0.05), and with high tumor purity (P<0.05) and high malignant progression (P<0.05) of the HCC.
CONCLUSIONS: The hnRNPU gene identified in this study may become a new biomarker for the diagnosis and prognosis of HCC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); heterogeneous nuclear ribonucleoprotein (hnRNPU); molecular biomarker

Year:  2021        PMID: 34790398      PMCID: PMC8576204          DOI: 10.21037/jgo-21-468

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  42 in total

1.  Actin and hnRNP U cooperate for productive transcription by RNA polymerase II.

Authors:  Alexander Kukalev; Ylva Nord; Carina Palmberg; Tomas Bergman; Piergiorgio Percipalle
Journal:  Nat Struct Mol Biol       Date:  2005-02-13       Impact factor: 15.369

2.  Mechanism of alternative splicing and its regulation.

Authors:  Yan Wang; Jing Liu; B O Huang; Yan-Mei Xu; Jing Li; Lin-Feng Huang; Jin Lin; Jing Zhang; Qing-Hua Min; Wei-Ming Yang; Xiao-Zhong Wang
Journal:  Biomed Rep       Date:  2014-12-17

Review 3.  Alternative splicing as a regulator of development and tissue identity.

Authors:  Francisco E Baralle; Jimena Giudice
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-10       Impact factor: 94.444

4.  hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

Authors:  Miguel Gallardo; Hun Ju Lee; Xiaorui Zhang; Carlos Bueso-Ramos; Laura R Pageon; Mark McArthur; Asha Multani; Aziz Nazha; Taghi Manshouri; Jan Parker-Thornburg; Inmaculada Rapado; Alfonso Quintas-Cardama; Steven M Kornblau; Joaquin Martinez-Lopez; Sean M Post
Journal:  Cancer Cell       Date:  2015-09-24       Impact factor: 31.743

5.  Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms.

Authors:  Hui Chen; Feng Gao; Mian He; Xiao Fan Ding; Aikha M Wong; Siu Ching Sze; Allen C Yu; Tingting Sun; Anthony W-H Chan; Xin Wang; Nathalie Wong
Journal:  Hepatology       Date:  2019-03-22       Impact factor: 17.425

6.  A nuclear localization domain in the hnRNP A1 protein.

Authors:  H Siomi; G Dreyfuss
Journal:  J Cell Biol       Date:  1995-05       Impact factor: 10.539

7.  Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.

Authors:  Asaf Shilo; Vered Ben Hur; Polina Denichenko; Ilan Stein; Eli Pikarsky; Jens Rauch; Walter Kolch; Lars Zender; Rotem Karni
Journal:  RNA       Date:  2014-02-26       Impact factor: 4.942

Review 8.  The hnRNP family: insights into their role in health and disease.

Authors:  Thomas Geuens; Delphine Bouhy; Vincent Timmerman
Journal:  Hum Genet       Date:  2016-05-23       Impact factor: 4.132

9.  Gene expression profiling reveals U1 snRNA regulates cancer gene expression.

Authors:  Zhi Cheng; Yu Sun; Xiaoran Niu; Yingchun Shang; Jishou Ruan; Ze Chen; Shan Gao; Tao Zhang
Journal:  Oncotarget       Date:  2017-12-01

10.  Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential.

Authors:  Hao Li; Jingwei Liu; Shixuan Shen; Di Dai; Shitong Cheng; Xiaolong Dong; Liping Sun; Xiaolin Guo
Journal:  J Cell Mol Med       Date:  2020-09-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.